Clinical Scorecard: ASCO 2026: Genomics Reveal HRD–Treatment Response Link

At a Glance

Key Highlights

• Study assessed 70-gene signature in breast cancer
• HRD highest in patients with high risk 2 score
• Basal-like high risk 2 shows highest HRD association
• Luminal high risk 2 shows increased HRD compared to luminal high risk 1
• High scores correlate with benefit from anthracyclines

Guideline-Based Recommendations

Diagnosis

• Utilize 70-gene assay to determine breast cancer risk categories

Management

• Consider anthracyclines for patients with high risk scores

Monitoring & Follow-up

• Monitor homologous recombination deficiency levels in breast cancer patients

Risks

• Higher HRD may indicate different treatment responses

Patient & Prescribing Data

Breast cancer patients categorized by risk scores

Higher HRD may enhance effectiveness of anthracyclines in high risk groups

Clinical Best Practices

• Assess HRD in breast cancer patients to inform treatment decisions
• Utilize gene signature assays for risk stratification

Related Resources & Content

• ASCO 2026 Presentation by Steven Isakoff